My Treatment Approach: Interpreting the Data for Early-Stage HR+ Breast Cancer

Stephanie Graff, MD, presents a clinical case of a patient who is diagnosed with HR+ early-stage breast cancer.

Rachel Layman, MD, describes her impression of the case and discusses risk assessment and a treatment plan for the patient.

Expert medical oncologists provide an overview of current endocrine therapy approved for early-stage breast cancer.

Stephanie Graff, MD, and Rachel Layman, MD, discuss the design and results of the monarchE trial, which evaluated abemaciclib plus endocrine therapy for HR+, HER2 negative, node positive, high-risk early breast cancer.

Stephanie Graff, MD, and Rachel Layman, MD, discuss how to individualize care with CDK4/6 inhibitors in patients with high-risk early breast cancer.

Experts in breast oncology review age-dependent outcomes with CDK 4/6 inhibitors.

Rachel Layman, MD, summarizes how to dose CDK4/6 inhibitors in different clinical settings.

Stephanie Graff, MD, and Rachel Layman, MD, discuss how they would apply the results of the monarchE trial to clinical case scenarios.

Experts in breast oncology discuss how they select endocrine therapy in BRCA1/BRCA2+ breast cancer.

Rachel Layman, MD, presents a clinical case of a patient who is diagnosed with HR+ early-stage breast cancer.

Stephanie Graff, MD, describes her impression of the case and discusses the risk for recurrence in this particular patient.

Stephanie Graff, MD, and Rachel Layman, MD, discuss the design and results of the NATALEE trial, which evaluated adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer.

Expert medical oncologists talk about the impact of NATALEE trial data on their medical practice.

Stephanie Graff, MD, and Rachel Layman, MD, review common toxicities and adverse effects to watch out for with endocrine therapy and CDK4/6 inhibitors, and how to manage these.

Expert medical oncologists take a step into the future and discuss developments within the adjuvant setting of early-stage breast cancer they are most excited about.